Form 4: SAB Biotherapeutics President Granted 3M Stock Options

SAB Biotherapeutics' President and Director, Eddie Joe Sullivan, was granted 3 million stock options with an exercise price of $2.17, vesting over four years.

Summary

• Eddie Joe Sullivan, President and Director of SAB Biotherapeutics, Inc. (SABS), was granted 3,000,000 stock options.
• The options have an exercise price of $2.17 per share.
• The grant date for these options was August 26, 2025, and they expire on August 26, 2035.
• The options were issued under the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
• The awards are contingent upon the Company receiving stockholder approval to amend the Plan to increase the number of shares available for issuance.
• The shares underlying the option vest over a four-year period: 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Sentiment

Score: 7

Explanation: The grant of a significant number of stock options to a key executive is generally positive as it aligns management's interests with shareholder value creation. However, the contingency of shareholder approval for the plan amendment introduces a slight uncertainty.

Positives

• The grant of 3,000,000 stock options to President and Director Eddie Joe Sullivan aligns management's long-term interests with shareholder value creation.
• The options are part of an established 2021 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The awards are subject to stockholder approval to amend the Plan, introducing a contingency that could delay or prevent the full realization of the grant.
• Potential future dilution for existing shareholders if all 3,000,000 options are exercised.

Risks

• The grant is contingent on stockholder approval to amend the 2021 Omnibus Equity Incentive Plan to increase available shares, which may not be secured.
• The value of the options is dependent on the future market price of SAB Biotherapeutics' common stock exceeding the $2.17 exercise price.
• The vesting schedule extends over four years, meaning the full incentive is realized only with sustained performance and continued employment.

Future Outlook

The grant of these stock options indicates an expectation of future growth and value creation by the company, as the options' value is tied to the stock price appreciating above the exercise price. The full realization of these awards is contingent on obtaining stockholder approval for an amendment to the equity incentive plan.

Management Comments

• The options represent a right to purchase shares of the Issuer's common stock pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
• The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to incentivize and retain key executives, aligning their financial interests with the long-term performance and growth of the company. This is particularly relevant in industries with long development cycles and significant R&D investments.

Comparison to Industry Standards

• Granting stock options as a form of executive compensation is a standard practice across the biotech industry, similar to companies like Moderna or BioNTech, which frequently use equity incentives to attract and retain top talent.
• The four-year vesting schedule is typical for executive equity awards, designed to encourage long-term commitment and performance, comparable to vesting schedules seen at companies such as Gilead Sciences or Amgen for their senior leadership.

Corporate Governance

Related Party Transactions

• The grant of 3,000,000 stock options to Eddie Joe Sullivan, President and Director, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of management's interests with long-term stock performance.
• Employees: The 2021 Omnibus Equity Incentive Plan provides a framework for equity compensation, potentially impacting other employees' incentives and retention.

Next Steps

• The Company needs to obtain stockholder approval to amend the 2021 Omnibus Equity Incentive Plan to increase the number of shares available for issuance.

Key Dates

Recommendation

The grant of stock options to a key executive, while a positive for aligning management incentives, is a standard compensation event and does not fundamentally alter the company's immediate financial outlook or operational performance. Investors should 'hold' and monitor the company's underlying business fundamentals and the outcome of the shareholder vote on the plan amendment, as well as future operational results.

Keywords

SAB Biotherapeutics, SABS, Stock Options, Executive Compensation, Form 4, Equity Incentive Plan, Eddie Joe Sullivan, Insider Transaction